Upupcoco personal page - To The Moon

Upupcoco

Upupcoco

No personal profile

51Follow

4Followers

1Topic

0Badge

10-28

$Datavault AI Inc.(DVLT)$

2024-05-03

$Atossa Genetics(ATOS)$ let's goooo

2021-02-08

$Tiger Brokers(TIGR)$To the moon!

2022-01-13

$Atossa Genetics(ATOS)$just need to hold

2021-02-04

$Atossa Genetics(ATOS)$On Fire

2021-02-14

$Tiger Brokers(TIGR)$Gogo

2021-06-11

$Apple(AAPL)$Just like ytd it is going down

2021-02-07

Lost trust alrdy ba

Sorry, the original content has been removed

2021-02-03

Legooo

Investors Are Snapping Up a New Space Stock, Sending Shares Rocketing

2021-06-11

$Apple(AAPL)$why pre market so strong?

2021-02-15

$Apple(AAPL)$When to go up?

2021-02-03

$Microsoft(MSFT)$leggo!

10-28

goog

08-18

$UnitedHealth(UNH)$

2021-05-31

No affect in stocksl price

Sorry, the original content has been removed

2021-03-29

Can trust them?

Sorry, the original content has been removed

2021-02-17

$Atossa Genetics(ATOS)$When will it rocket

2021-02-13

Nice article thank you

Sorry, the original content has been removed

2021-02-09

Dunno wen it will drop aslo... scary

Sorry, the original content has been removed

2024-06-19

Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572220240591289","uuid":"3572220240591289","gmtCreate":1609149713664,"gmtModify":1714746624273,"name":"Upupcoco","pinyin":"upupcoco","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":51,"tweetSize":39,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.02","exceedPercentage":"60.48%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":2,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":494064485487536,"gmtCreate":1761647386080,"gmtModify":1761647388638,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DVLT\">$Datavault AI Inc.(DVLT)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/DVLT\">$Datavault AI Inc.(DVLT)$ </a>&nbsp;","text":"$Datavault AI Inc.(DVLT)$","images":[{"img":"https://community-static.tradeup.com/news/55c93a49413fd7e4f9f5f571d565f747","width":"894","height":"1564"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494064485487536","isVote":1,"tweetType":1,"viewCount":995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":494062513242632,"gmtCreate":1761646896874,"gmtModify":1761646900841,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"goog","listText":"goog","text":"goog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494062513242632","isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":468957787333488,"gmtCreate":1755529817983,"gmtModify":1755529819076,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/UNH\">$UnitedHealth(UNH)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/UNH\">$UnitedHealth(UNH)$&nbsp;</a>&nbsp;","text":"$UnitedHealth(UNH)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/468957787333488","isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":318641827393720,"gmtCreate":1718806849980,"gmtModify":1718808419993,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks","listText":"Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks","text":"Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/318641827393720","isVote":1,"tweetType":1,"viewCount":2932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":301979757121696,"gmtCreate":1714744950306,"gmtModify":1714744953737,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$ </a> let's goooo","listText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$ </a> let's goooo","text":"$Atossa Genetics(ATOS)$ let's goooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/301979757121696","isVote":1,"tweetType":1,"viewCount":2230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":283212469870592,"gmtCreate":1710172179525,"gmtModify":1710172182896,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Let's gooooo","listText":"Let's gooooo","text":"Let's gooooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/283212469870592","repostId":"2417357296","repostType":2,"repost":{"id":"2417357296","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1709731800,"share":"https://ttm.financial/m/news/2417357296?lang=en_US&edition=fundamental","pubTime":"2024-03-06 21:30","market":"sg","language":"en","title":"Press Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2417357296","media":"Dow Jones","summary":"Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research  Annual Meeting. \"We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,\" said Dr. Steven Quay, Atossa's President and Chief Executive Officer. \"While neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal. An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur. There is growing excitement and understanding across the breast cancer community that -endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women.\"","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting \n</p>\n<p>\n  SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic <a href=\"https://laohu8.com/S/PK\">$(PK)$</a> run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The EVANGELINE study is investigating <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer. \n</p>\n<p>\n  \"We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,\" said Dr. Steven Quay, Atossa's President and Chief Executive Officer. \"While neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal. An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur. There is growing excitement and understanding across the breast cancer community that (Z)-endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women.\" \n</p>\n<p>\n  Details of the presentation are: \n</p>\n<pre>\n   -- Session Title: Phase II Clinical Trials 1 \n \n   -- Abstract Title: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- \n      breast cancer: Evaluation of the first pharmacokinetic cohort of the \n      EVANGELINE trial \n \n   -- Session Date and Time: Tuesday April 9, 2024 -- 9:00 AM - 12:30 PM \n \n   -- Abstract Presentation Number: CT205 \n</pre>\n<p>\n  The full abstract text will be posted to the AACR online itinerary planner and meeting app at 3:00 pm ET on Friday, April 5, 2024. \n</p>\n<p>\n  Organized by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20,000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualized patient care, and showcases the best and most up-to-date cancer science available. \n</p>\n<p>\n  About EVANGELINE \n</p>\n<p>\n  EVANGELINE (Endoxifen --Versus exemestANe GosEreLIn, NCT05607004) is a randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. Participants receive neoadjuvant treatment for up to six months, followed by surgery. The primary objective of the EVANGELINE study is to determine whether the endocrine sensitive disease (ESD) rate, measured by Ki-67 (a proliferation marker prognostic for disease free survival), after four weeks of treatment with (Z)-endoxifen is non-inferior to the ESD rate following treatment with current standard of care, exemestane plus goserelin. Exemestane is an aromatase inhibitor designed to block the synthesis of estrogen and slow the growth of ER+ cancers. Goserelin is a medication given to block the ovaries from making estrogen, which in premenopausal women is associated with significant morbidity and inadequate compliance, which compromises efficacy and increases the risk of mortality. \n</p>\n<p>\n  About Premenopausal Patients with ER+ / HER2- Breast Cancer \n</p>\n<p>\n  Breast cancer is the most frequently diagnosed cancer in premenopausal women worldwide and accounts for almost half of the cancers that occur in women aged 15-49. An overwhelming majority (.APPROX.75%) of premenopausal breast cancer falls under luminal A (ER+/HER2-) or B (ER+/HER2+) subtypes. Ovarian function suppression, when combined with either tamoxifen or an aromatase inhibitor, is the current standard of care for the endocrine management of stage 2 and 3 premenopausal ER+/HER2- breast cancer. \n</p>\n<p>\n  About (Z)-Endoxifen \n</p>\n<p>\n  (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKC&lt;BETA&gt;1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. \n</p>\n<p>\n  Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive <a href=\"https://laohu8.com/S/E\">$(E)$</a>-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase 1 studies and in a Phase 2 study of women with breast cancer. (Z)-endoxifen is currently being studied in four Phase 2 trials: one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies including the EVANGELINE study in women with ER+/HER2- breast cancer. Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications. \n</p>\n<p>\n  About Atossa Therapeutics \n</p>\n<p>\n  Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com \n</p>\n<p>\n  Contact \n</p>\n<p>\n  Eric Van Zanten \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Investor and Public Relations \n</p>\n<p>\n  610-529-6219 \n</p>\n<p>\n  eric.vanzanten@atossainc.com \n</p>\n<p>\n  FORWARD-LOOKING STATEMENTS \n</p>\n<p>\n  This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as \"expect,\" \"potential,\" \"continue, \" \"may,\" \"will,\" \"should,\" \"could,\" \"would,\" \"seek,\" \"intend,\" \"plan,\" \"estimate,\" \"anticipate,\" \"believe,\" \"future,\" or other comparable words. All statements other than statements of historical fact, including statements regarding the timing of data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, guidance, industry prospects, or future results of operations or financial position made in this press release are forward-looking. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to regain compliance with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 06, 2024 08:30 ET (13:30 GMT)\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-03-06 21:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting \n</p>\n<p>\n  SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic <a href=\"https://laohu8.com/S/PK\">$(PK)$</a> run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The EVANGELINE study is investigating <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer. \n</p>\n<p>\n  \"We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,\" said Dr. Steven Quay, Atossa's President and Chief Executive Officer. \"While neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal. An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur. There is growing excitement and understanding across the breast cancer community that (Z)-endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women.\" \n</p>\n<p>\n  Details of the presentation are: \n</p>\n<pre>\n   -- Session Title: Phase II Clinical Trials 1 \n \n   -- Abstract Title: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- \n      breast cancer: Evaluation of the first pharmacokinetic cohort of the \n      EVANGELINE trial \n \n   -- Session Date and Time: Tuesday April 9, 2024 -- 9:00 AM - 12:30 PM \n \n   -- Abstract Presentation Number: CT205 \n</pre>\n<p>\n  The full abstract text will be posted to the AACR online itinerary planner and meeting app at 3:00 pm ET on Friday, April 5, 2024. \n</p>\n<p>\n  Organized by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20,000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualized patient care, and showcases the best and most up-to-date cancer science available. \n</p>\n<p>\n  About EVANGELINE \n</p>\n<p>\n  EVANGELINE (Endoxifen --Versus exemestANe GosEreLIn, NCT05607004) is a randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. Participants receive neoadjuvant treatment for up to six months, followed by surgery. The primary objective of the EVANGELINE study is to determine whether the endocrine sensitive disease (ESD) rate, measured by Ki-67 (a proliferation marker prognostic for disease free survival), after four weeks of treatment with (Z)-endoxifen is non-inferior to the ESD rate following treatment with current standard of care, exemestane plus goserelin. Exemestane is an aromatase inhibitor designed to block the synthesis of estrogen and slow the growth of ER+ cancers. Goserelin is a medication given to block the ovaries from making estrogen, which in premenopausal women is associated with significant morbidity and inadequate compliance, which compromises efficacy and increases the risk of mortality. \n</p>\n<p>\n  About Premenopausal Patients with ER+ / HER2- Breast Cancer \n</p>\n<p>\n  Breast cancer is the most frequently diagnosed cancer in premenopausal women worldwide and accounts for almost half of the cancers that occur in women aged 15-49. An overwhelming majority (.APPROX.75%) of premenopausal breast cancer falls under luminal A (ER+/HER2-) or B (ER+/HER2+) subtypes. Ovarian function suppression, when combined with either tamoxifen or an aromatase inhibitor, is the current standard of care for the endocrine management of stage 2 and 3 premenopausal ER+/HER2- breast cancer. \n</p>\n<p>\n  About (Z)-Endoxifen \n</p>\n<p>\n  (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKC&lt;BETA&gt;1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. \n</p>\n<p>\n  Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive <a href=\"https://laohu8.com/S/E\">$(E)$</a>-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase 1 studies and in a Phase 2 study of women with breast cancer. (Z)-endoxifen is currently being studied in four Phase 2 trials: one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies including the EVANGELINE study in women with ER+/HER2- breast cancer. Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications. \n</p>\n<p>\n  About Atossa Therapeutics \n</p>\n<p>\n  Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com \n</p>\n<p>\n  Contact \n</p>\n<p>\n  Eric Van Zanten \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, Investor and Public Relations \n</p>\n<p>\n  610-529-6219 \n</p>\n<p>\n  eric.vanzanten@atossainc.com \n</p>\n<p>\n  FORWARD-LOOKING STATEMENTS \n</p>\n<p>\n  This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as \"expect,\" \"potential,\" \"continue, \" \"may,\" \"will,\" \"should,\" \"could,\" \"would,\" \"seek,\" \"intend,\" \"plan,\" \"estimate,\" \"anticipate,\" \"believe,\" \"future,\" or other comparable words. All statements other than statements of historical fact, including statements regarding the timing of data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, guidance, industry prospects, or future results of operations or financial position made in this press release are forward-looking. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to regain compliance with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 06, 2024 08:30 ET (13:30 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","E":"埃尼石油","BK4181":"酒店及度假村房地产投资信托","ATOS":"Atossa Genetics Inc","BK4218":"酒店及度假村房地产信托","BK4551":"寇图资本持仓","Z":"Zillow","BK4201":"综合性石油与天然气企业","BK4548":"巴美列捷福持仓","BK4585":"ETF&股票定投概念","BK4079":"房地产服务","PK":"Park Hotels & Resorts Inc."},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2417357296","content_text":"Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting \n\n\n  SEATTLE, March 06, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced today that data from the 40mg pharmacokinetic $(PK)$ run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The EVANGELINE study is investigating $(Z)$-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer. \n\n\n  \"We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,\" said Dr. Steven Quay, Atossa's President and Chief Executive Officer. \"While neoadjuvant therapy is effective and widely used across many cancer types, the current treatment options for premenopausal women diagnosed with ER+ breast cancer are sub-optimal. An effective and tolerable neoadjuvant therapy would transform the treatment approach in this setting, making surgery more effective and reducing the likelihood that the cancer will recur. There is growing excitement and understanding across the breast cancer community that (Z)-endoxifen, if shown to be safe and effective, would be a game changer for premenopausal women.\" \n\n\n  Details of the presentation are: \n\n\n   -- Session Title: Phase II Clinical Trials 1 \n \n   -- Abstract Title: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- \n      breast cancer: Evaluation of the first pharmacokinetic cohort of the \n      EVANGELINE trial \n \n   -- Session Date and Time: Tuesday April 9, 2024 -- 9:00 AM - 12:30 PM \n \n   -- Abstract Presentation Number: CT205 \n\n\n  The full abstract text will be posted to the AACR online itinerary planner and meeting app at 3:00 pm ET on Friday, April 5, 2024. \n\n\n  Organized by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20,000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualized patient care, and showcases the best and most up-to-date cancer science available. \n\n\n  About EVANGELINE \n\n\n  EVANGELINE (Endoxifen --Versus exemestANe GosEreLIn, NCT05607004) is a randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. Participants receive neoadjuvant treatment for up to six months, followed by surgery. The primary objective of the EVANGELINE study is to determine whether the endocrine sensitive disease (ESD) rate, measured by Ki-67 (a proliferation marker prognostic for disease free survival), after four weeks of treatment with (Z)-endoxifen is non-inferior to the ESD rate following treatment with current standard of care, exemestane plus goserelin. Exemestane is an aromatase inhibitor designed to block the synthesis of estrogen and slow the growth of ER+ cancers. Goserelin is a medication given to block the ovaries from making estrogen, which in premenopausal women is associated with significant morbidity and inadequate compliance, which compromises efficacy and increases the risk of mortality. \n\n\n  About Premenopausal Patients with ER+ / HER2- Breast Cancer \n\n\n  Breast cancer is the most frequently diagnosed cancer in premenopausal women worldwide and accounts for almost half of the cancers that occur in women aged 15-49. An overwhelming majority (.APPROX.75%) of premenopausal breast cancer falls under luminal A (ER+/HER2-) or B (ER+/HER2+) subtypes. Ovarian function suppression, when combined with either tamoxifen or an aromatase inhibitor, is the current standard of care for the endocrine management of stage 2 and 3 premenopausal ER+/HER2- breast cancer. \n\n\n  About (Z)-Endoxifen \n\n\n  (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKC<BETA>1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. \n\n\n  Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive $(E)$-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase 1 studies and in a Phase 2 study of women with breast cancer. (Z)-endoxifen is currently being studied in four Phase 2 trials: one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies including the EVANGELINE study in women with ER+/HER2- breast cancer. Atossa's (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications. \n\n\n  About Atossa Therapeutics \n\n\n  Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com \n\n\n  Contact \n\n\n  Eric Van Zanten \n\n\nVP, Investor and Public Relations \n\n\n  610-529-6219 \n\n\n  eric.vanzanten@atossainc.com \n\n\n  FORWARD-LOOKING STATEMENTS \n\n\n  This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as \"expect,\" \"potential,\" \"continue, \" \"may,\" \"will,\" \"should,\" \"could,\" \"would,\" \"seek,\" \"intend,\" \"plan,\" \"estimate,\" \"anticipate,\" \"believe,\" \"future,\" or other comparable words. All statements other than statements of historical fact, including statements regarding the timing of data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, guidance, industry prospects, or future results of operations or financial position made in this press release are forward-looking. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to regain compliance with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2024 08:30 ET (13:30 GMT)","news_type":1,"symbols_score_info":{"ATOS":0.9,"PK":1,"E":1,"Z":1}},"isVote":1,"tweetType":1,"viewCount":2656,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185656479342608,"gmtCreate":1686365828836,"gmtModify":1686365833917,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"I want to earn money","listText":"I want to earn money","text":"I want to earn money","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185656479342608","isVote":1,"tweetType":1,"viewCount":2694,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002730517,"gmtCreate":1642087953702,"gmtModify":1676533679891,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$</a>just need to hold","listText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$</a>just need to hold","text":"$Atossa Genetics(ATOS)$just need to hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002730517","isVote":1,"tweetType":1,"viewCount":3247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188324774,"gmtCreate":1623422223798,"gmtModify":1704203325235,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just like ytd it is going down","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just like ytd it is going down","text":"$Apple(AAPL)$Just like ytd it is going down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188324774","isVote":1,"tweetType":1,"viewCount":3451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181529465,"gmtCreate":1623402666357,"gmtModify":1704202636853,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>why pre market so strong?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>why pre market so strong?","text":"$Apple(AAPL)$why pre market so strong?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181529465","isVote":1,"tweetType":1,"viewCount":3410,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581744193958444","authorId":"3581744193958444","name":"ninjainvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"idStr":"3581744193958444","authorIdStr":"3581744193958444"},"content":"pre market was strong last couple of days but didn persist throughout the day, price weaken when market opens! Hope today goes to the moon!","text":"pre market was strong last couple of days but didn persist throughout the day, price weaken when market opens! Hope today goes to the moon!","html":"pre market was strong last couple of days but didn persist throughout the day, price weaken when market opens! Hope today goes to the moon!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110210657,"gmtCreate":1622458244579,"gmtModify":1704184692411,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"No affect in stocksl price","listText":"No affect in stocksl price","text":"No affect in stocksl price","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110210657","repostId":"2139437460","repostType":2,"isVote":1,"tweetType":1,"viewCount":2263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":352420984,"gmtCreate":1616995422548,"gmtModify":1704800576614,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Can trust them?","listText":"Can trust them?","text":"Can trust them?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/352420984","repostId":"2123286076","repostType":4,"isVote":1,"tweetType":1,"viewCount":3200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":387926793,"gmtCreate":1613712109612,"gmtModify":1704883963560,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Just a thought....&nbsp;should buy now... what is the bet that they tey to drive the price low and later on they huy the dip!","listText":"Just a thought....&nbsp;should buy now... what is the bet that they tey to drive the price low and later on they huy the dip!","text":"Just a thought.... should buy now... what is the bet that they tey to drive the price low and later on they huy the dip!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/387926793","repostId":"1107899645","repostType":4,"repost":{"id":"1107899645","kind":"news","pubTimestamp":1613704060,"share":"https://ttm.financial/m/news/1107899645?lang=en_US&edition=fundamental","pubTime":"2021-02-19 11:07","market":"us","language":"en","title":"Palantir stock slumps as lockup expiration opens 80% of shares for trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1107899645","media":"Seeking Alpha","summary":"Palantir Technologies Inc. 's direct listing in September unusually included a lockup period, which ","content":"<p><a href=\"https://laohu8.com/S/PLTR\">Palantir Technologies Inc.</a> 's&nbsp;direct listing in September unusually included a lockup period, which expires today. Insiders were only allowed to sell 20%of their shares in the listing, which means the remaining 80% are open for trading today. Palantir shares aredown 5.8%pre-market.</p>\n<p>Palantir has faced valuation concerns with shares closing yesterday at about 274% above its direct listing reference price.</p>\n<p>Soros Fund Management will continue exiting its position that amounted to&nbsp; 18.46M shares as of November, when the fund said it regretted the investment and \"does not approve of Palantir's business practices.\"</p>\n<p>The fund said at the time it had sold all the shares it could and would keep selling,when permitted.</p>\n<p><img src=\"https://static.tigerbbs.com/4eb04e82d11b2b74032cb91d003dd907\" tg-width=\"540\" tg-height=\"445\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir stock slumps as lockup expiration opens 80% of shares for trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir stock slumps as lockup expiration opens 80% of shares for trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-19 11:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3663407-palantir-stock-slumps-as-lockup-expiration-opens-80-of-shares-for-trading><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies Inc. 's direct listing in September unusually included a lockup period, which expires today. Insiders were only allowed to sell 20%of their shares in the listing, which means the...</p>\n\n<a href=\"https://seekingalpha.com/news/3663407-palantir-stock-slumps-as-lockup-expiration-opens-80-of-shares-for-trading\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/news/3663407-palantir-stock-slumps-as-lockup-expiration-opens-80-of-shares-for-trading","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107899645","content_text":"Palantir Technologies Inc. 's direct listing in September unusually included a lockup period, which expires today. Insiders were only allowed to sell 20%of their shares in the listing, which means the remaining 80% are open for trading today. Palantir shares aredown 5.8%pre-market.\nPalantir has faced valuation concerns with shares closing yesterday at about 274% above its direct listing reference price.\nSoros Fund Management will continue exiting its position that amounted to  18.46M shares as of November, when the fund said it regretted the investment and \"does not approve of Palantir's business practices.\"\nThe fund said at the time it had sold all the shares it could and would keep selling,when permitted.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":2173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385222915,"gmtCreate":1613556621037,"gmtModify":1704881981098,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>When will it rocket","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>When will it rocket","text":"$Atossa Genetics(ATOS)$When will it rocket","images":[{"img":"https://static.tigerbbs.com/e82026ee8fc078c781991196970358bd","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/385222915","isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382850910,"gmtCreate":1613433350630,"gmtModify":1704880384309,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Why it this rising czily?","listText":"Why it this rising czily?","text":"Why it this rising czily?","images":[{"img":"https://static.tigerbbs.com/27cef1b75ffc5af52293a81343a21288","width":"750","height":"1646"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382850910","isVote":1,"tweetType":1,"viewCount":882,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382981886,"gmtCreate":1613349104045,"gmtModify":1704879958189,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>When to go up?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>When to go up?","text":"$Apple(AAPL)$When to go up?","images":[{"img":"https://static.tigerbbs.com/4cd25f4b57a3368a878be8bf9282d524","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382981886","isVote":1,"tweetType":1,"viewCount":1102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382046870,"gmtCreate":1613317876890,"gmtModify":1704879885180,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Gogo","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Gogo","text":"$Tiger Brokers(TIGR)$Gogo","images":[{"img":"https://static.tigerbbs.com/129131c96c421c3862fbecd2a82664d2","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/382046870","isVote":1,"tweetType":1,"viewCount":2223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":386223000,"gmtCreate":1613187476500,"gmtModify":1704879320624,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Nice article thank you","listText":"Nice article thank you","text":"Nice article thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386223000","repostId":"1179092967","repostType":4,"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":381317421,"gmtCreate":1612930966763,"gmtModify":1704876162051,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"Very hard to speculate.. Historically, yes I feel likethere would be some kind of correction soon.. But, this time it may not follow the history and go long for a quite long time...","listText":"Very hard to speculate.. Historically, yes I feel likethere would be some kind of correction soon.. But, this time it may not follow the history and go long for a quite long time...","text":"Very hard to speculate.. Historically, yes I feel likethere would be some kind of correction soon.. But, this time it may not follow the history and go long for a quite long time...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/381317421","repostId":"1169253231","repostType":4,"repost":{"id":"1169253231","kind":"news","pubTimestamp":1612926685,"share":"https://ttm.financial/m/news/1169253231?lang=en_US&edition=fundamental","pubTime":"2021-02-10 11:11","market":"us","language":"en","title":"Is the stock market due for a correction in 2021? Here’s what some experts think","url":"https://stock-news.laohu8.com/highlight/detail?id=1169253231","media":"MarketWatch","summary":"A pullback for the Dow Jones Industrial Average and the S&P 500 index on Tuesday halted the longest ","content":"<p>A pullback for the Dow Jones Industrial Average and the S&amp;P 500 index on Tuesday halted the longest win streak for stocks in months, but a major concern for investors remains: Is there a major correction looming ahead?</p>\n<p>Even some bullish investors have called for a retrenchment in stocks as a sort of catharsis for the next leg higher and an unwind of some of the frenzied, retail-inspired betting that has repeatedly sent stocks to fresh records amid the COVID-19 recovery.</p>\n<p>A brief pullback that began in late January, tied to the trading fervor around GameStop Corp.&nbsp;and AMC Entertainment Holdings,saw markets test some short-term bullish trend lines, but recently the markets have managed to claw back to produce not-unspectacular returns in the early goings of a year chock-full of uncertainties.</p>\n<p>The Dow Jones Industrial Average&nbsp;is up 2.5% so far in the year, the S&amp;P 500&nbsp;is enjoying a more pronounced gain of over 4%, while the Nasdaq Composite&nbsp;and Russell 2000&nbsp;indexes on Tuesday notched their 10th record closes in 2021 thus far.</p>\n<p>The year-to-date gains in the large-cap Nasdaq, up 8.7%, and the Russell 2000, up 16.4%, reflect an odd convergence of investor bets: Those wagering on further prosperity in COVID-tested, large-capitalization growth stocks that worked in the aftermath of the pandemic in the U.S. back in March, alongside bets for a sizable rebound in small-cap, economically sensitive stocks represented in the Russell.</p>\n<p>In either case, cautious investors and those worried that the good times can’t last forever are bracing for the next major slump for stocks, and ruminating on how it might play out.</p>\n<p>Earlier this week, Morgan Stanley’s Michael Wilson&nbsp;told CNBC during an interview&nbsp;that “It was brief, so if you blinked you missed it,” referring to the pullback in stocks in late January.</p>\n<p>“That looks like that was it for now, and I mean, the markets are quite powerful at the moment, and they have been,” Wilson said.</p>\n<p>“There’s tremendous liquidity, there’s a very good and very understandable story behind the scenes. Meaning, we’ve got a strong economic recovery that’s visible to everyone. The earnings season’s been good so far…and people have bought into it,” the Morgan Stanley analyst said.</p>\n<p>He cautioned, however, that the market remains in a “a bit of a fragile state,” and warned that leverage swirling in the system could make pullbacks of 3% or 5% more of the norm.</p>\n<p>Wilson did say, however, that the re-emergence of individual investors in financial markets would be a force to be reckoned with, and that they currently represent the marginal buyer on Wall Street keeping asset prices buoyant.</p>\n<p>Keith&nbsp;Lerner, chief market strategist at Truist Advisory Services, said that concerns of a stock bubble are overdone and not supported by the current batch of fourth-quarter earnings results, which his firm estimates will be the best since the 2008 financial crisis.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/614ce86d6f888394bc0303ea4afc4f16\" tg-width=\"1212\" tg-height=\"914\"><span>TRUIST ADVISORY SERVICES INC./SUNTRUST ADVISORY SERVICES INC.</span></p>\n<p>“Although there are frothy segments of the market that are detached from fundamentals, we do not see bubble conditions more broadly,” Lerner wrote in a research report dated Tuesday.</p>\n<p>“Instead, we see a stock market that is trading at a premium to historical valuations—partly justified by low rates, a shift in sector composition toward higher-valued growth sectors, supportive monetary and fiscal policy, as well as cheaper access to markets (i.e., secular decline in commissions and fund fees),” the Truist analysts added, noting that a lower barrier to entry for individual investors also was providing support for stock values.</p>\n<p>Meanwhile, Daniel Pinto, a co-president at JPMorgan Chase &amp; Co.,told CNBC in a Q&amp;A&nbsp;that he expects the stock market to grind higher.</p>\n<p>“I think the market will gradually grind up during the year,” he told the news network. “I don’t see a correction anytime soon, unless the situation changes dramatically,” he said, describing possible downturns as mini corrections that won’t necessarily change the overall bullish trend.</p>\n<p>What could change things?</p>\n<p>Naeem Aslam, chief market analyst at AvaTrade, in a Tuesday report said that optimism in the U.S. market is driven by three actors: Support from monetary and fiscal policy, progress in COVID vaccinations and the solid quarterly results.</p>\n<p>“Basically, it seems like the stars are getting in line, and there are strong odds stacked in favour of another bull rally,” Aslam wrote.</p>\n<p>“In other words, we need something major changing in the current catalyst to shift the market narrative among traders that can trigger a minor pullback—let alone a serious correction,” he added.</p>\n<p>MarketWatch’s William Watts writes&nbsp;that some experts are pointing to the 2009 stock market as the closest parallel to the current setup for equities. Quoting Tony Dwyer, chief market strategist at Canaccord Genuity, Watts noted that 2021 could play out more like the postcrisis scenario seen in 2010, which would point the way to a “solid year” for the market, but with a bumpy ride thanks to “multiple first-half corrections.”</p>\n<p>Some of the bumpiness might emanate from the bond market, with the 10-yearTMUBMUSD10Y,1.162%and 30-year TreasurysTMUBMUSD30Y,1.950%testing recent yield highs and putting some pressure on equities.</p>\n<p>The so-called reflation trade, where yields rise and investors gravitate to investments that might prosper in better economic times, has provided a number of false dawns for investors so far.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the stock market due for a correction in 2021? Here’s what some experts think</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the stock market due for a correction in 2021? Here’s what some experts think\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-10 11:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/is-the-stock-market-due-for-a-correction-in-2021-heres-what-some-experts-think-11612916422?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A pullback for the Dow Jones Industrial Average and the S&P 500 index on Tuesday halted the longest win streak for stocks in months, but a major concern for investors remains: Is there a major ...</p>\n\n<a href=\"https://www.marketwatch.com/story/is-the-stock-market-due-for-a-correction-in-2021-heres-what-some-experts-think-11612916422?mod=home-page\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.marketwatch.com/story/is-the-stock-market-due-for-a-correction-in-2021-heres-what-some-experts-think-11612916422?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1169253231","content_text":"A pullback for the Dow Jones Industrial Average and the S&P 500 index on Tuesday halted the longest win streak for stocks in months, but a major concern for investors remains: Is there a major correction looming ahead?\nEven some bullish investors have called for a retrenchment in stocks as a sort of catharsis for the next leg higher and an unwind of some of the frenzied, retail-inspired betting that has repeatedly sent stocks to fresh records amid the COVID-19 recovery.\nA brief pullback that began in late January, tied to the trading fervor around GameStop Corp. and AMC Entertainment Holdings,saw markets test some short-term bullish trend lines, but recently the markets have managed to claw back to produce not-unspectacular returns in the early goings of a year chock-full of uncertainties.\nThe Dow Jones Industrial Average is up 2.5% so far in the year, the S&P 500 is enjoying a more pronounced gain of over 4%, while the Nasdaq Composite and Russell 2000 indexes on Tuesday notched their 10th record closes in 2021 thus far.\nThe year-to-date gains in the large-cap Nasdaq, up 8.7%, and the Russell 2000, up 16.4%, reflect an odd convergence of investor bets: Those wagering on further prosperity in COVID-tested, large-capitalization growth stocks that worked in the aftermath of the pandemic in the U.S. back in March, alongside bets for a sizable rebound in small-cap, economically sensitive stocks represented in the Russell.\nIn either case, cautious investors and those worried that the good times can’t last forever are bracing for the next major slump for stocks, and ruminating on how it might play out.\nEarlier this week, Morgan Stanley’s Michael Wilson told CNBC during an interview that “It was brief, so if you blinked you missed it,” referring to the pullback in stocks in late January.\n“That looks like that was it for now, and I mean, the markets are quite powerful at the moment, and they have been,” Wilson said.\n“There’s tremendous liquidity, there’s a very good and very understandable story behind the scenes. Meaning, we’ve got a strong economic recovery that’s visible to everyone. The earnings season’s been good so far…and people have bought into it,” the Morgan Stanley analyst said.\nHe cautioned, however, that the market remains in a “a bit of a fragile state,” and warned that leverage swirling in the system could make pullbacks of 3% or 5% more of the norm.\nWilson did say, however, that the re-emergence of individual investors in financial markets would be a force to be reckoned with, and that they currently represent the marginal buyer on Wall Street keeping asset prices buoyant.\nKeith Lerner, chief market strategist at Truist Advisory Services, said that concerns of a stock bubble are overdone and not supported by the current batch of fourth-quarter earnings results, which his firm estimates will be the best since the 2008 financial crisis.\nTRUIST ADVISORY SERVICES INC./SUNTRUST ADVISORY SERVICES INC.\n“Although there are frothy segments of the market that are detached from fundamentals, we do not see bubble conditions more broadly,” Lerner wrote in a research report dated Tuesday.\n“Instead, we see a stock market that is trading at a premium to historical valuations—partly justified by low rates, a shift in sector composition toward higher-valued growth sectors, supportive monetary and fiscal policy, as well as cheaper access to markets (i.e., secular decline in commissions and fund fees),” the Truist analysts added, noting that a lower barrier to entry for individual investors also was providing support for stock values.\nMeanwhile, Daniel Pinto, a co-president at JPMorgan Chase & Co.,told CNBC in a Q&A that he expects the stock market to grind higher.\n“I think the market will gradually grind up during the year,” he told the news network. “I don’t see a correction anytime soon, unless the situation changes dramatically,” he said, describing possible downturns as mini corrections that won’t necessarily change the overall bullish trend.\nWhat could change things?\nNaeem Aslam, chief market analyst at AvaTrade, in a Tuesday report said that optimism in the U.S. market is driven by three actors: Support from monetary and fiscal policy, progress in COVID vaccinations and the solid quarterly results.\n“Basically, it seems like the stars are getting in line, and there are strong odds stacked in favour of another bull rally,” Aslam wrote.\n“In other words, we need something major changing in the current catalyst to shift the market narrative among traders that can trigger a minor pullback—let alone a serious correction,” he added.\nMarketWatch’s William Watts writes that some experts are pointing to the 2009 stock market as the closest parallel to the current setup for equities. Quoting Tony Dwyer, chief market strategist at Canaccord Genuity, Watts noted that 2021 could play out more like the postcrisis scenario seen in 2010, which would point the way to a “solid year” for the market, but with a bumpy ride thanks to “multiple first-half corrections.”\nSome of the bumpiness might emanate from the bond market, with the 10-yearTMUBMUSD10Y,1.162%and 30-year TreasurysTMUBMUSD30Y,1.950%testing recent yield highs and putting some pressure on equities.\nThe so-called reflation trade, where yields rise and investors gravitate to investments that might prosper in better economic times, has provided a number of false dawns for investors so far.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":878,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":383965170,"gmtCreate":1612830980990,"gmtModify":1704874709874,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572220240591289","authorIdStr":"3572220240591289"},"themes":[],"htmlText":"..... dogecoin?? Seriously??","listText":"..... dogecoin?? Seriously??","text":"..... dogecoin?? Seriously??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383965170","repostId":"1163750848","repostType":4,"isVote":1,"tweetType":1,"viewCount":646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":494064485487536,"gmtCreate":1761647386080,"gmtModify":1761647388638,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DVLT\">$Datavault AI Inc.(DVLT)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/DVLT\">$Datavault AI Inc.(DVLT)$ </a>&nbsp;","text":"$Datavault AI Inc.(DVLT)$","images":[{"img":"https://community-static.tradeup.com/news/55c93a49413fd7e4f9f5f571d565f747","width":"894","height":"1564"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494064485487536","isVote":1,"tweetType":1,"viewCount":995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":301979757121696,"gmtCreate":1714744950306,"gmtModify":1714744953737,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$ </a> let's goooo","listText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$ </a> let's goooo","text":"$Atossa Genetics(ATOS)$ let's goooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/301979757121696","isVote":1,"tweetType":1,"viewCount":2230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389124583,"gmtCreate":1612742146442,"gmtModify":1704873681787,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>To the moon!&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>To the moon!&nbsp;","text":"$Tiger Brokers(TIGR)$To the moon!","images":[{"img":"https://static.tigerbbs.com/6a965664eb2faf3671e41dc12ed466c9","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/389124583","isVote":1,"tweetType":1,"viewCount":587,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9002730517,"gmtCreate":1642087953702,"gmtModify":1676533679891,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$</a>just need to hold","listText":"<a href=\"https://ttm.financial/S/ATOS\">$Atossa Genetics(ATOS)$</a>just need to hold","text":"$Atossa Genetics(ATOS)$just need to hold","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002730517","isVote":1,"tweetType":1,"viewCount":3247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317061460,"gmtCreate":1612398850050,"gmtModify":1704870619907,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>On Fire","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>On Fire","text":"$Atossa Genetics(ATOS)$On Fire","images":[{"img":"https://static.tigerbbs.com/9aefdb7e9a91cad4e738ac79b0e32952","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/317061460","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382046870,"gmtCreate":1613317876890,"gmtModify":1704879885180,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Gogo","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>Gogo","text":"$Tiger Brokers(TIGR)$Gogo","images":[{"img":"https://static.tigerbbs.com/129131c96c421c3862fbecd2a82664d2","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/382046870","isVote":1,"tweetType":1,"viewCount":2223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":188324774,"gmtCreate":1623422223798,"gmtModify":1704203325235,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just like ytd it is going down","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Just like ytd it is going down","text":"$Apple(AAPL)$Just like ytd it is going down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188324774","isVote":1,"tweetType":1,"viewCount":3451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389949276,"gmtCreate":1612671990195,"gmtModify":1704873432551,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"Lost trust alrdy ba","listText":"Lost trust alrdy ba","text":"Lost trust alrdy ba","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/389949276","repostId":"2109722637","repostType":4,"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314800216,"gmtCreate":1612326139535,"gmtModify":1704869759689,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"Legooo","listText":"Legooo","text":"Legooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/314800216","repostId":"1183975527","repostType":4,"repost":{"id":"1183975527","kind":"news","pubTimestamp":1612319838,"share":"https://ttm.financial/m/news/1183975527?lang=en_US&edition=fundamental","pubTime":"2021-02-03 10:37","market":"us","language":"en","title":"Investors Are Snapping Up a New Space Stock, Sending Shares Rocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=1183975527","media":"barrons","summary":"Investors are excitedabout space—and they are jumping ona dealthat will bring another fledgling spac","content":"<p>Investors are excitedabout space—and they are jumping ona dealthat will bring another fledgling space company to public markets.</p>\n<p>Tuesday, space-launch company Astra announced it is merging with special purpose acquisition companyHolicity(ticker: HOL). When the merger is complete, the new company with trade under the stock symbol “ASTR.” Until then, space investors can buy Holicity stock. Indeed, they have started to already. Holicity shares were up more than 50% in Tuesday afternoon trading.</p>\n<p>“This transaction takes us a step closer to our mission of improving life on Earth from space by fully funding our plan to provide daily access to low Earth orbit from anywhere on the planet,” said Astra founder and CEO Chris Kemp in the company’snews release.</p>\n<p>The merger gives Astra a pro-forma market capitalization of almost $4.1 billion.</p>\n<p>The number of space stocks and data points is growing like, well, the constellation of satellites circling the globe.Lockheed Martin(LMT), for starters, recently paid about$4.4 billionto acquireAerojet Rocketdyne(ARJD). Space-logistics providerMomentusis merging withStable Road Acquisition(SRAC), giving Momentus a market capitalization of about $3.4 billion based on 151 million shares outstanding when the merger closes.</p>\n<p>Space-tourism pioneerVirgin Galactic(SPCE) has achieved a $12 billion market cap along with a strong following on Wall Street. Six Wall Street analysts rate the shares Buy, while three others rate the sharesHold. The average Buy-rating ratio for stocks in theDow Jones Industrial Averageis about 57%.</p>\n<p>Virgin Orbit is another space-launch services company that recently reached orbit. It is still privately held, not yet finding a SPAC merger partner.</p>\n<p>SpaceXis privately held, as well. Elon Musk’s space firm is the largest of the lot, valued at an estimated $46 billion. SpaceX pioneered the use of reusable rockets, helping to spark the space gold rush. Along with carrying astronautsfor NASAto the International Space Station, the company is launching itsStarlink satellitesto build a global, space-based Wi-Fi business.</p>\n<p>Astra’s rockets don’t appear to be reusable; it is lowering launch costs in other ways. “We’ve invested in machines and infrastructure to produce rockets at scale,” says Kemp ina video tourof the company’s manufacturing facility. Reaching orbit used to take tens of millions of dollars. New companies are lowering the bill to millions of dollars.</p>\n<p>Falling costs are opening outer space for business. For exactly what, however, is still a guess. “Were going to see new applications that no one has ever imagined that will help improve life on earth,” says Kemp. Among the possibilities that people are imagining are new communications technologies like the ones SpaceX is pursuing, detailed earth observation, early-warning systems for defense, and weather and GPS applications.</p>\n<p>Astra appears confident that new applications are coming. The company has ambitions to have daily orbital launches by 2025. Revenue is projected to reach $1.5 billion that year, and Astra projects almost $700 million in free cash flow.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors Are Snapping Up a New Space Stock, Sending Shares Rocketing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors Are Snapping Up a New Space Stock, Sending Shares Rocketing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-03 10:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/holicity-shares-rocket-higher-on-news-of-the-spacs-merger-with-astra-51612296073?mod=hp_LEADSUPP_3><strong>barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors are excitedabout space—and they are jumping ona dealthat will bring another fledgling space company to public markets.\nTuesday, space-launch company Astra announced it is merging with ...</p>\n\n<a href=\"https://www.barrons.com/articles/holicity-shares-rocket-higher-on-news-of-the-spacs-merger-with-astra-51612296073?mod=hp_LEADSUPP_3\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.barrons.com/articles/holicity-shares-rocket-higher-on-news-of-the-spacs-merger-with-astra-51612296073?mod=hp_LEADSUPP_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183975527","content_text":"Investors are excitedabout space—and they are jumping ona dealthat will bring another fledgling space company to public markets.\nTuesday, space-launch company Astra announced it is merging with special purpose acquisition companyHolicity(ticker: HOL). When the merger is complete, the new company with trade under the stock symbol “ASTR.” Until then, space investors can buy Holicity stock. Indeed, they have started to already. Holicity shares were up more than 50% in Tuesday afternoon trading.\n“This transaction takes us a step closer to our mission of improving life on Earth from space by fully funding our plan to provide daily access to low Earth orbit from anywhere on the planet,” said Astra founder and CEO Chris Kemp in the company’snews release.\nThe merger gives Astra a pro-forma market capitalization of almost $4.1 billion.\nThe number of space stocks and data points is growing like, well, the constellation of satellites circling the globe.Lockheed Martin(LMT), for starters, recently paid about$4.4 billionto acquireAerojet Rocketdyne(ARJD). Space-logistics providerMomentusis merging withStable Road Acquisition(SRAC), giving Momentus a market capitalization of about $3.4 billion based on 151 million shares outstanding when the merger closes.\nSpace-tourism pioneerVirgin Galactic(SPCE) has achieved a $12 billion market cap along with a strong following on Wall Street. Six Wall Street analysts rate the shares Buy, while three others rate the sharesHold. The average Buy-rating ratio for stocks in theDow Jones Industrial Averageis about 57%.\nVirgin Orbit is another space-launch services company that recently reached orbit. It is still privately held, not yet finding a SPAC merger partner.\nSpaceXis privately held, as well. Elon Musk’s space firm is the largest of the lot, valued at an estimated $46 billion. SpaceX pioneered the use of reusable rockets, helping to spark the space gold rush. Along with carrying astronautsfor NASAto the International Space Station, the company is launching itsStarlink satellitesto build a global, space-based Wi-Fi business.\nAstra’s rockets don’t appear to be reusable; it is lowering launch costs in other ways. “We’ve invested in machines and infrastructure to produce rockets at scale,” says Kemp ina video tourof the company’s manufacturing facility. Reaching orbit used to take tens of millions of dollars. New companies are lowering the bill to millions of dollars.\nFalling costs are opening outer space for business. For exactly what, however, is still a guess. “Were going to see new applications that no one has ever imagined that will help improve life on earth,” says Kemp. Among the possibilities that people are imagining are new communications technologies like the ones SpaceX is pursuing, detailed earth observation, early-warning systems for defense, and weather and GPS applications.\nAstra appears confident that new applications are coming. The company has ambitions to have daily orbital launches by 2025. Revenue is projected to reach $1.5 billion that year, and Astra projects almost $700 million in free cash flow.","news_type":1,"symbols_score_info":{"SPCE":0.9}},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181529465,"gmtCreate":1623402666357,"gmtModify":1704202636853,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>why pre market so strong?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>why pre market so strong?","text":"$Apple(AAPL)$why pre market so strong?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181529465","isVote":1,"tweetType":1,"viewCount":3410,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581744193958444","authorId":"3581744193958444","name":"ninjainvest","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3581744193958444","idStr":"3581744193958444"},"content":"pre market was strong last couple of days but didn persist throughout the day, price weaken when market opens! Hope today goes to the moon!","text":"pre market was strong last couple of days but didn persist throughout the day, price weaken when market opens! Hope today goes to the moon!","html":"pre market was strong last couple of days but didn persist throughout the day, price weaken when market opens! Hope today goes to the moon!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382981886,"gmtCreate":1613349104045,"gmtModify":1704879958189,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>When to go up?","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>When to go up?","text":"$Apple(AAPL)$When to go up?","images":[{"img":"https://static.tigerbbs.com/4cd25f4b57a3368a878be8bf9282d524","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382981886","isVote":1,"tweetType":1,"viewCount":1102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":314370575,"gmtCreate":1612314748897,"gmtModify":1704869608790,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MSFT\">$Microsoft(MSFT)$</a>leggo!","listText":"<a href=\"https://laohu8.com/S/MSFT\">$Microsoft(MSFT)$</a>leggo!","text":"$Microsoft(MSFT)$leggo!","images":[{"img":"https://static.tigerbbs.com/a88fcc4ac439b40070089783543489ed","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/314370575","isVote":1,"tweetType":1,"viewCount":478,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"Finally, when your initial post [Bixin] [Bixin] comes, I hope you can have a good time and earn a good time in Tiger Community! If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when your initial post [Bixin] [Bixin] comes, I hope you can have a good time and earn a good time in Tiger Community! If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when your initial post [Bixin] [Bixin] comes, I hope you can have a good time and earn a good time in Tiger Community! If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":494062513242632,"gmtCreate":1761646896874,"gmtModify":1761646900841,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"goog","listText":"goog","text":"goog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/494062513242632","isVote":1,"tweetType":1,"viewCount":496,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":468957787333488,"gmtCreate":1755529817983,"gmtModify":1755529819076,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/UNH\">$UnitedHealth(UNH)$&nbsp;</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/UNH\">$UnitedHealth(UNH)$&nbsp;</a>&nbsp;","text":"$UnitedHealth(UNH)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/468957787333488","isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":110210657,"gmtCreate":1622458244579,"gmtModify":1704184692411,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"No affect in stocksl price","listText":"No affect in stocksl price","text":"No affect in stocksl price","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/110210657","repostId":"2139437460","repostType":2,"isVote":1,"tweetType":1,"viewCount":2263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":352420984,"gmtCreate":1616995422548,"gmtModify":1704800576614,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"Can trust them?","listText":"Can trust them?","text":"Can trust them?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/352420984","repostId":"2123286076","repostType":4,"isVote":1,"tweetType":1,"viewCount":3200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":385222915,"gmtCreate":1613556621037,"gmtModify":1704881981098,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>When will it rocket","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>When will it rocket","text":"$Atossa Genetics(ATOS)$When will it rocket","images":[{"img":"https://static.tigerbbs.com/e82026ee8fc078c781991196970358bd","width":"828","height":"1434"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/385222915","isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":386223000,"gmtCreate":1613187476500,"gmtModify":1704879320624,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"Nice article thank you","listText":"Nice article thank you","text":"Nice article thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386223000","repostId":"1179092967","repostType":4,"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":383966659,"gmtCreate":1612830873871,"gmtModify":1704874707775,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"Dunno wen it will drop aslo... scary","listText":"Dunno wen it will drop aslo... scary","text":"Dunno wen it will drop aslo... scary","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383966659","repostId":"1133468331","repostType":4,"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":318641827393720,"gmtCreate":1718806849980,"gmtModify":1718808419993,"author":{"id":"3572220240591289","authorId":"3572220240591289","name":"Upupcoco","avatar":"https://community-static.tradeup.com/news/662a3462603575f69fb9259f404f88df","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572220240591289","idStr":"3572220240591289"},"themes":[],"htmlText":"Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks","listText":"Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks","text":"Just relax with family member, put my phone aside and focus famly time, eat nice food , snacks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/318641827393720","isVote":1,"tweetType":1,"viewCount":2932,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}